Thx. I got it / understood. I will make more DD re. diarrhea and stool form and frequency changes for my final conclusion.
e.g.: AMPLIFY study
The single adverse event with a placebo-adjusted rate greater than 3% was loose stools/diarrhea at 36%, where most incidents were reported within the first five days of treatment, were transient in nature and the median time to resolution was four days after onset. Notably, only 2.6% of patients in the tenapanor arm discontinued treatment due to loose stools/diarrhea, as compared to 0.8% in the binder arm.
G
ps.: What is your view about
(i) FGEN (Roxadustat / anemia of chronic kidney disease (CKD), in both non-dialysis-dependent and dialysis-dependent patients) and
(ii) CARA (KORSUVA (CR845/difelikefalin) injection / Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus)
Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Notice: This post is not investment advice, and not a recommendation to neither buy nor hold nor sell.
Recent ARDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:53:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:50:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:48:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 01:01:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 08:12:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 10:29:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:00:55 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 10:09:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 12:57:53 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 05/30/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:58:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:21:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:19:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:17:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:08:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:07:06 PM
- Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2024 12:02:00 PM
- Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults • GlobeNewswire Inc. • 05/21/2024 12:02:21 PM
- Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) • GlobeNewswire Inc. • 05/16/2024 12:01:41 PM
- Ardelyx, Inc. Reports Employment Inducement Grants • GlobeNewswire Inc. • 05/14/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:03:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:48:10 PM
- Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference • GlobeNewswire Inc. • 05/07/2024 12:01:45 PM
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/02/2024 08:02:28 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM